<DOC>
	<DOCNO>NCT01798368</DOCNO>
	<brief_summary>The purpose study demonstrate treatment cause clinically significant effect would put patient risk .</brief_summary>
	<brief_title>PBASE-system Safety Tolerability Clinical Investigation</brief_title>
	<detailed_description />
	<criteria>Willing able provide write informed consent prior participation clinical investigation Judged Investigator suitable participation study without safety concern base medical history , physical examination laboratory result Age : 1865 year age . Gender : Male female subject . Negative urine drug screen ( amphetamine , benzodiazepine , cocaine , marijuana , metamphetamine , morphine ) screen Visit 2 . Female subject postmenopausal one year use highly efficient method contraception ( i.e . method le 1 % failure rate [ e.g . sterilisation , hormone implant , hormone injection , intrauterine device , abstinence , vasectomise partner ] ) . Oral contraceptive : combine pill ( estrogen / progestin ) mediumdose progestin pill ( example desogestrel 75ug ) accept combination partner use condom . Willing able comply study procedure restriction A diagnosis asthma chronic obstructive pulmonary disorder . Ongoing respiratory infection include nasal cavity . Current malignancy kind . History frequent nose bleeds condition increase risk excessive bleeding . Pronounced anterior septal deviation significant nasal pathology . Known allergy polyvinylchloride medicinal liquid paraffin . Ongoing treatment drug indicate respiratory cardiac disorder . Any disease , condition ( medical surgical ) include allergic , immunological gastrointestinal condition and/or chronic medication , opinion investigator , might compromise study result , would place subject increase risk . Vital sign clinically significant deviation would make subject unsuitable study , judge investigator . Evidence significant cardiovascular disease define follow : 1 . New York Heart Association ( NYHA ) Class III IV heart failure ; 2 . Presence symptomatic coronary artery disease unstable angina ; 3 . Persistent arrhythmia require chronic pharmacotherapy implantable device ; 4 . Clinically significant abnormality see screen electrocardiogram assess investigator ; Clinically significant deviation , hematology ( include coagulation parameter aPTT INR ) variable , blood chemistry variable urinalysis assessed investigator . Positive screen test HIV hepatitis B C Positive alcohol breath test Visit 1 Visit 2 . Nonsmoker since least six month time screen . Is currently implanted electrical and/or neurostimulator device , include limited cardiac pacemaker , defibrillator , vagal neurostimulator , deep brain stimulator , spinal stimulator , bone growth stimulator , cochlear implant . Previously treat radiation face Previous radiation therapy head neck region Previously treat implantable stimulator implantable device head / neck Has recent repeat history syncope . Has recent repeat history seizure . Surgery within past three month , determine PI clinically relevant . Strenuous exercise within 2 day Visit 1 Visit 2 . Women pregnant nursing . Female subject : unwilling use adequate contraceptive measure sign inform consent end study followup visit . Received study drug clinical trial investigational drug within previous 30 day , 5 halflives , whichever longer . Blood donation loss whole blood exceed 100 mL within 30 day screen plasma within 14 day screen . Excessive intake alcohol , defined average daily intake great three unit , maximum weekly intake great 21 unit ( ( three unit equal 250 ml 12 % alcohol unit wine ) . Concurrent condition risk noncompliance , investigator 's opinion , may affect interpretation performance safety data otherwise contraindicate participation clinical investigation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>